Results 81 to 90 of about 149,933 (301)

Nanomedicine for the Treatment of Non-Hodgkin Lymphoma [PDF]

open access: yes, 2019
Non-Hodgkin lymphoma, or NHL, is the predominant category of lymphoma. NHL is a type of lymphoid hematopoietic malignancy which approximately 70,000 Americans are diagnosed with annually, with the number of diagnoses growing annually.
Gandhi, B.Pharm, Tanvi
core   +1 more source

Long‐Term Quality of Life in 1777 Persons With Hodgkin Lymphoma and 6166 Matched Comparators

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Survival has improved substantially for patients with Hodgkin lymphoma (HL), but long‐term quality of life (QoL) remains incompletely understood. This was a Danish, nationwide, cross‐sectional study of QoL among persons with a diagnosis of HL matched 1:10 to general population comparators.
Sissel Johanne Godtfredsen   +13 more
wiley   +1 more source

Different faces of cutaneous Hodgkin′s disease

open access: yesIndian Journal of Dermatopathology and Diagnostic Dermatology, 2014
Hodgkin′s disease with skin involvement is a rare entity with a reported incidence of 0.5-3.5%. Various routes of skin involvement may include retrograde lymphatic spread, direct extension from underlying nodes, or hematogenous spread.
Shikha Goyal   +5 more
doaj   +1 more source

Malignant lymphomas (ML) and HIV/AIDS Infection in Tanzania. [PDF]

open access: yes, 2008
\ud HIV infection is reported to be associated with some malignant lymphomas (ML) so called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis.
Amos R Mwakigonja   +45 more
core   +2 more sources

Real‐World Outcomes of Mycosis Fungoides and Site‐Specific Nodal Involvement: A Registry‐Based Study of 25 467 Patients

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Mycosis fungoides (MF) is a rare extranodal T‐cell lymphoma with primary cutaneous involvement. While it is the most common primary skin lymphoma, large‐scale real‐world data defining survival benchmarks and the prognostic significance of specific nodal sites remain limited.
Charalampos Filippatos   +4 more
wiley   +1 more source

UPDATES ON HODGKIN DISEASE

open access: yesHematology, Transfusion and Cell Therapy
Hodgkin Lymphoma (HL) is a B-cell malignancy accounting for approximately 10% of all lymphoma cases and 5% of lymphoma-related mortalities. Incidence increases in younger adults and those above 55-years of age and has a bimodal distribution ...
Valeh Huseynov
doaj   +1 more source

Life Is in the Blood [PDF]

open access: yes, 2019
It takes about 60 seconds for all the blood in your body to complete its journey. It travels from your heart to your extremities and returns, there and back again.
Conrad, Jason, Gillen, Alan L.
core   +1 more source

Another treatment option for relapsed or refractory chronic lymphocytic leukaemia. [PDF]

open access: yes, 2017
We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome.
Mauro, Francesca Romana
core   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

open access: yesArthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Epstein-Barr virus latent membrane protein-1 expression in Hodgkin lymphoma

open access: yesBangabandhu Sheikh Mujib Medical University Journal, 2018
Expression of latent membrane protein-1 of Epstein-Barr virus is documented in Hodgkin lymphoma indicating its relationship in disease process.
Ferdousy Begum   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy